TEST CHANGE

Keppra (Levetiracetam)

0098627, KEPPRA

Specimen Requirements:	
Patient Preparation:	Timing of specimen collection: Predose~~Pre-dose~~ (trough) draw at~~- At~~ steady state concentration.
Collect:	Plain red. Also acceptable: Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).
Specimen Preparation:	Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP standard transport tube.~~Standard Transport Tube.~~ (Min: 0.3 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Serum or plasma separator tubes. Grossly hemolyzed specimens.
Remarks:	
Stability:	After separation from cells: Ambient: 7 days; Refrigerated: 1 week; Frozen: 1 month
Methodology:	Quantitative Enzyme Immunoassay (EIA)
Performed:	Sun-Sat
Reported:	Within 24 hours
Note:	
CPT Codes:	80177
New York DOH Approval Status:	This test is New York DOH approved.

Interpretive Data:

Pharmacokinetics of levetiracetam are affected by renal function. Adverse effects may include somnolence, weakness, headache and vomiting.

This levetiracetam (Keppra) immunoassay uses the ARK Diagnostics reagents, which has known cross-reactivity with the drug brivaracetam (Briviact) and may report inaccurate results. Patients transitioning from levetiracetam to brivaracetam or those who are using both medications should not monitor drug concentrations with the ARK Diagnostics assay. These patients should be monitored using a validated chromatographic methodology that distinguishes between drugs to determine drug concentrations.

Reference Interval:

Effective February 22, 2022

Therapeutic range: : 10-40 μg/mL
Toxic: Not well established

HOTLINE NOTE: There is a numeric map change associated with this test. Refer to the Hotline Test Mix for interface build information.